Last reviewed · How we verify
Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients
This is a prospective, randomized clinical trial to investigate the clinical impact of a preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients. Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of therapy or clinical management alone. Scores on self-reported measures of depressive and anxiety symptoms along with quality of life will be compared between cohorts.
Details
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 99 |
| Start date | Wed Sep 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Oct 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Depression
- Anxiety
- Generalized Anxiety Disorder
- Depressive Disorder
- Major Depressive Disorder
- Cancer
Interventions
- DNA-guided choice of therapy
- Clinical management
Countries
United States